Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect.

Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect.
复制标题

DOI:
10.1016/j.cell.2015.04.016
复制
发表时间:
2015-05-21
期刊:
影响因子:
64.5
通讯作者:
Ravetch JV
Ravetch JV
中科院分区:
生物学1区
文献类型:
--
作者:
DiLillo DJ;Ravetch JV

文献摘要

参考文献

被引文献

相似文献

被动施用的抗肿瘤单克隆抗体通过 FcγR 介导的细胞毒性 (ADCC)(一个短期过程)快速杀死肿瘤靶标。然而,抗肿瘤单克隆抗体治疗也可以诱导疫苗效应,其中单克隆抗体介导的肿瘤死亡诱导长期的抗肿瘤细胞免疫反应。为了确定这种反应是如何产生的,我们利用了针对模型新抗原的抗肿瘤疫苗作用的小鼠模型。我们证明 CD11c+ 抗原呈递细胞表达 FcγR 是在 ADCC 介导的肿瘤清除后产生抗肿瘤 T 细胞反应所必需的。使用 FcγR 人源化小鼠,我们证明抗肿瘤 huIgG1 必须与巨噬细胞上的 hFcγRIIIA 结合以介导 ADCC,但也与 hFcγRIIA(人类 DC 表达的唯一 hFcγR)结合,以产生有效的疫苗效应。因此,虽然仅与 hFcγRIIIA 结合增强的下一代抗肿瘤抗体现已投入临床使用,但理想的抗肿瘤抗体必须针对细胞毒性作用以及 hFcγRIIA 对 DC 的参与进行优化,以刺激长期抗肿瘤细胞免疫。
Passively-administered anti-tumor mAbs rapidly kill tumor targets via FcγR-mediated cytotoxicity (ADCC), a short-term process. However, anti-tumor mAb treatment can also induce a vaccinal effect, in which mAb-mediated tumor death induces a long-term anti-tumor cellular immune response. To determine how such responses are generated, we utilized a murine model of an anti-tumor vaccinal effect against a model neoantigen. We demonstrate that FcγR expression by CD11c+ antigen-presenting cells is required to generate anti-tumor T cell responses upon ADCC-mediated tumor clearance. Using FcγR-humanized mice, we demonstrate that anti-tumor huIgG1 must engage hFcγRIIIA on macrophages to mediate ADCC, but also engage hFcγRIIA, the sole hFcγR expressed by human DCs, to generate a potent vaccinal effect. Thus, while next-generation anti-tumor antibodies with enhanced binding to only hFcγRIIIA are now in clinical use, ideal anti-tumor antibodies must be optimized for both cytotoxic effects as well as hFcγRIIA engagement on DCs to stimulate long-term anti-tumor cellular immunity.
DOI: 10.1056/nejmoa1003466
发表时间: 2010-08-19
期刊: The New England journal of medicine
影响因子: --
作者:
Hodi FS;O'Day SJ;McDermott DF;Weber RW;Sosman JA;Haanen JB;Gonzalez R;Robert C;Schadendorf D;Hassel JC;Akerley W;van den Eertwegh AJ;Lutzky J;Lorigan P;Vaubel JM;Linette GP;Hogg D;Ottensmeier CH;Lebbé C;Peschel C;Quirt I;Clark JI;Wolchok JD;Weber JS;Tian J;Yellin MJ;Nichol GM;Hoos A;Urba WJ
通讯作者: Urba WJ
DOI: 10.4161/onci.29311
发表时间: 2014
期刊: Oncoimmunology
影响因子: 7.2
作者:
Fritsch EF;Hacohen N;Wu CJ
通讯作者: Wu CJ
DOI: 10.1006/clim.2001.5115
发表时间: 2001-12-01
影响因子: 8.6
作者:
Berlyn, KA;Schultes, B;Mann, DL
通讯作者: Mann, DL
DOI: 10.1172/jci24772
发表时间: 2005-10-01
影响因子: 15.9
作者:
Boruchov, AM;Heller, G;Young, JW
通讯作者: Young, JW
DOI: 10.1182/blood-2008-10-185280
发表时间: 2009-04-16
期刊: BLOOD
影响因子: 20.3
作者:
Hilchey, Shannon P.;Hyrien, Ollivier;Bernstein, Steven H.
通讯作者: Bernstein, Steven H.